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hypertension compared with the lowest intake (OR 0.69, 
95% CI 0.48, 0.98) in women. There was no significant 
association in men. Among main classes of polyphenols, 
flavonoids and phenolic acids were independent contribu-
tors to this association. The analysis of individual sub-
classes of polyphenol revealed that, among phenolic acids, 
hydroxycynnamic acids were independently associated to 
lower odds of hypertension (OR 0.66, 95% CI 0.47, 0.93), 
while among flavonoids, most of the association was driven 
by flavanols (OR 0.56, 95% CI 0.36, 0.87).
Conclusion Certain classes of dietary polyphenols were 
associated with lower risk of hypertension, but potential 
differences between men and women should be further 
investigated.
Keywords Hypertension · Dietary polyphenols · 
Flavonoids · Phenolic acids · Flavanols
Introduction
Polyphenols are a group of molecules contained in a wide 
variety of foods and beverages commonly consumed by 
humans [1]. These compounds are divided into five main 
classes according to their chemical structure: flavonoids, 
phenolic acids, stilbenes, lignans, and others [2]. Their 
absorption and bioactivity have been reported to vary with 
a great extent depending on their chemical structure [3]. 
Out of thousands identified phenolic compounds, only a 
limited number have been estimated to significantly con-
tribute to daily dietary intake [4]. Nevertheless, despite 
high variability in inter- and intra-individual intake and 
absorption and great differences in bioavailability, polyphe-
nols have been extensively studied in both epidemiological 
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and experimental studies for their potential health effects 
due to anti-oxidant and anti-inflammatory properties [5 ].
A growing interest on association of dietary polyphe-
nol intake with major cardiovascular risk factors has been 
the focus of recent research. Following in vitro and in vivo 
studies demonstrating significant effect in regulating 
inflammatory status [6], several epidemiological investiga-
tions tested the association between polyphenol intake and 
hypertension [7–14], although most of them only included 
dietary flavonoids [7–10] and lignans [11, 12]. Overall, 
studies reported inconsistent results. Findings may vary 
between studies because of differences in food composition 
tables and dietary assessment methodologies used. Given 
the documented heterogeneity in structural characteristics, 
bioavailability, absorption, and metabolism, it is of main 
interest to investigate the independent effect of each poly-
phenol group analyzed comprehensively. Moreover, foods 
and beverages contributing to their intake vary between 
countries in terms of both quantity and quality, which in 
turn may be responsible for most of the observed differ-
ences on consumption of individual polyphenol group. 
Current research on dietary polyphenol intake and CVD 
risk factors is promising, but not conclusive. Moreover, 
studies with comprehensive estimation of all major classes 
and subclasses of polyphenols are lacking and further evi-
dence is needed. Thus, the aim of this study was to assess 
whether total, individual classes, and subclasses of dietary 
polyphenol intake were associated with average blood pres-
sure and incident cases of hypertension in the Polish arm 
of the Health, Alcohol and Psychosocial factors In Eastern 
Europe (HAPIEE) study.
Methods
Study population
The HAPIEE study is a multicenter prospective cohort 
study investigating the role of biological, dietary, lifestyle, 
and environmental factors in cardiovascular and other 
chronic diseases in Eastern European countries [15]. The 
study protocol and the methodology used were reported in 
details elsewhere [15]. In the present study, only data from 
the Polish cohort were included. Briefly, a random sample 
of 10,729 individuals (aged 45–69 years) was recruited at 
the baseline survey (first wave) conducted in 2002–2005 
(response ratio of 59%) in the urban area of Krakow, 
Poland. The participants provided written informed con-
sent to complete a structured questionnaire and undergo a 
clinical examination. The present study was conducted on 
those individuals free of hypertension at baseline. Out of 
the 8822 individuals with available clinical information at 
baseline, a total of 2725 participants free of hypertension 
at baseline attended the last follow-up visit conducted in 
2006–2008 and thus were included in the present study. 
Participants were followed for a median follow-up period 
of 4 years (range 3.2–5.4 years). Sample included in the 
analysis did not substantially differ in background charac-
teristics or variables of interest concerning polyphenol con-
sumption compared with the baseline examination (data not 
shown).
Dietary assessment
Dietary data were collected using a 148-item food fre-
quency questionnaire (FFQ) previously validated [16, 17]. 
Estimation of portion sizes was facilitated using photo-
graphic references. Participants were asked how often, on 
average, they had consumed that amount of the item during 
the last 3 months, with nine responses ranging from ‘never 
or less than once per month’ to ‘six or more times per day.’ 
Moreover, participants were asked to include additional 
drinks and foods and frequency of consumption by manual 
entry.
Estimation of polyphenol intake
Data on the polyphenol content in foods were obtained 
from the Phenol-Explorer database (http://www.phenol-
explorer.eu) [18]. The process of estimation of polyphenol 
intake has been described in details elsewhere [19]. Briefly, 
food items of the FFQ containing more food components 
were separated according to their ingredients and foods that 
contained no polyphenols were excluded from the analysis. 
The average food consumption was calculated (in g or ml) 
by following the standard portion sizes used in the study 
and then converted in 24-h intake. An advanced search 
was carried out in the Phenol-Explorer database to retrieve 
mean content values for all polyphenols contained in the 
foods obtained, and individual polyphenol intake from each 
food was calculated by multiplying the content of each 
polyphenol by the daily consumption of each food. Total 
polyphenol intake was calculated as the sum of all individ-
ual polyphenol intakes from all food sources encountered 
according to this process. In this study, we investigated 
exposure to total polyphenols and their main classes phe-
nolic acids, flavonoids, stilbenes, and lignans; the main 
subclasses of phenolic acids, including hydroxybenzoic 
acids and hydroxycinnamic acids; the main subclasses of 
flavonoids, including flavanols, flavonols, flavanones, fla-
vones, anthocyanins, and isoflavones; and “other” poly-
phenols, including alkylmethoxyphenols, alkylphenols, 
curcuminoids, furanocoumarins, hydroxybenzaldehydes, 
hydroxybenzoketones, hydroxycinnamaldehydes, hydroxy-
coumarins, hydroxyphenylpropenes, methoxyphenols, 
naphtoquinones, phenolic terpenes, and tyrosols.
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Demographic, lifestyle, and clinical measurements
Sociodemographic and lifestyle characteristics included 
age, gender, educational and occupational level, smoking, 
and alcohol drinking habits. Physical activity included 
energy expenditure in leisure time by reporting type and 
duration of activity according to the predetermined ques-
tionnaire items. The overall amount of energy expenditure 
was estimated in kcal/day and categorized in low, moder-
ate, and high physical activity level. Individuals were cat-
egorized according their smoking status as (i) non-smokers 
and (ii) current smokers. Average alcohol consumption was 
categorized as (i) none or low (≤12 g/day) and (ii) alcohol 
drinker (>12 g/day).
Physical examination included measurement of height, 
weight, waist circumference, and blood pressure using 
standard procedures [15]. Body mass index (BMI) was cal-
culated according to the formula weight (kg)/height (m)2. 
Blood pressure was measured three times at the end of the 
physical examination, and the final value was the mean 
among the second and third measurements.
Ascertainment of hypertension and incident events
Participants were considered to have hypertension at base-
line visit if they had a having systolic and/or a diastolic 
blood pressure measurement equal to or higher than 140 
and 90 mmHg, respectively, or taking hypertensive medi-
cation within the last 2 weeks. The same procedures were 
applied at follow-up visits.
Statistical analysis
Characteristics of the study cohort were described by 
baseline polyphenol consumption categories. Taking 
into account the natural differences in hypertension risk 
between men and women, gender-specific analyses were 
conducted. Descriptive presentation relied on cross tab-
ulations. Continuous variables were presented as means 
and standard deviations (SDs), categorical variables as 
percentages. Variables were examined for normality 
(Kolmogorov test). Chi-square test was used for com-
parisons of categorical variables, Kruskal–Wallis test 
was used for continuous variables. The linear association 
between total and individual classes and subclasses of 
polyphenol intake and systolic and diastolic blood pres-
sure measurements at follow-up visits was tested though 
linear regression analysis models. Odds ratios (ORs) and 
95% confidence intervals (CIs) of hypertension compar-
ing the various categories of exposure (total and indi-
vidual classes of polyphenol intake) with the lowest 
one (reference category) were calculated by performing 
age- and energy-adjusted and multivariate-adjusted logis-
tic regression models. Variables included in the multi-
variable model were age, total energy intake, body mass 
index, physical activity, educational status, smoking sta-
tus, alcohol consumption, menopausal status (women 
only), and all main classes of polyphenols. When examin-
ing the association with total polyphenols, a sensitivity 
analysis was performed by including one at the time the 
major food sources of polyphenols based on our previous 
publication [20], to test whether the level of association 
was mainly driven by one individual food component. 
Statistical significance was accepted at P < 0.05. All sta-
tistical analyses were performed with SPSS for Windows 
21.0 (SPSS Inc, Chicago, IL).
Results
Baseline characteristics of individuals free of hyperten-
sion by quartiles of total polyphenol intake are presented 
in Table  1. There were no significant differences in the 
distribution of baseline characteristics by intake of total 
polyphenol with the exception of age (higher consum-
ers were younger) and in total energy (in women only), 
sodium, and potassium intake (Table  1). Among total 
and individual classes of polyphenols, phenolic acids and 
their subclasses hydroxybenzoic and hydroxycinnamic 
acids were linearly inversely associated with systolic 
blood pressure measurements at follow-up visit in women 
but not in men (Supplementary Table 1). Also the group 
of other polyphenols was associated with lower both, 
systolic and diastolic blood pressure in women (Supple-
mentary Table  1). In men, only stilbenes were linearly 
inversely associated with systolic blood pressure (Supple-
mentary Table 1).
During 4-year follow-up, 1735 incident cases of hyper-
tension occurred. In the multivariate model, the highest 
quartile of total polyphenol intake was associated with 
31% decreased risk of hypertension compared with the 
lowest (OR 0.69, 95% CI 0.48, 0.98; Table 2) in women 
but not in men. The sensitivity analysis by adjusting for 
major food sources of polyphenols did not change the 
retrieved associations (data not shown). Among main 
classes of polyphenols, flavonoids, phenolic acids, and 
other polyphenols were independent contributors to this 
association. The analysis of individual subclasses of 
polyphenol revealed that, among phenolic acids, hydrox-
ycynnamic acids were independently associated with 
lower odds of develop hypertension (OR 0.66, 95% CI 
0.47, 0.93), while among flavonoids, most of the associa-
tion was driven by flavanols (OR 0.56, 95% CI 0.36, 0.87; 
Table 3). No significant associations were found in men.
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Discussion
In this study, we investigated the association between 
total and individual classes of polyphenol intake and inci-
dence of hypertension in urban population. We found that 
women with higher intake of polyphenols were less likely 
to develop hypertension compared to lower ones. Among 
specific classes and subclasses of polyphenols, higher con-
sumption of flavonoids, phenolic acids, and “other” poly-
phenols was inversely associated with incident cases of 
hypertension. These results are in accordance with previous 
findings provided by a cross-sectional study conducted on 
Table 2  Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between cumulative polyphenol intake (total and main 
groups) and incidence of hypertension
a Age- and energy-adjusted
b Adjusted for age, total energy intake, body mass index, physical activity, educational status, smoking status, alcohol consumption (yes/no and 
continuous), sodium, potassium and fiber intake, menopausal status (women only), and all main classes of polyphenols included in the table
Polyphenol quartiles, Men Polyphenol quartiles, Women
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Total polyphe-
nols, mean 
(SD)
1024.9 
(208.3)
1471.9 
(103.1)
1866.9 
(137.7)
2658.5 
(586.1)
1035.8 
(214.9)
1470.7 
(101.3)
1878.5 
(136.6)
2598.3 (559.9)
Incicent 
hyperten-
sion, n (%)
171 (67.9) 184 (66.4) 209 (68.1) 200 (63.5) 221 (67.0) 232 (60.9) 267 (65.0) 251 (55.5)
OR (95% CI)a 1 0.96 (0.66, 
1.38)
1.07 (0.74, 
1.55)
0.90 (0.61, 
1.31)
1 0.77 (0.56, 
1.05)
0.92 (0.67, 
1.26)
0.62 (0.45, 
0.84)
OR (95% CI)b 1 1.03 (0.66, 
1.59)
1.07 (0.70, 
1.65)
1.03 (0.65, 
1.62)
1 0.80 (0.56, 
1.14)
0.97 (0.68, 
1.39)
0.68 (0.48, 
0.87)
Flavonoids, 
mean (SD)
503.1 (121.1) 754.7 (55.3) 957.4 (69.5) 1474.1 
(474.3)
504.0 (122.5) 758.1 (54.7) 956.9 (70.2) 1452.9 (482.0)
OR (95%CI)a 1 0.99 (0.98, 
1.01)
0.94 (0.66, 
1.35)
1.13 (0.76, 
1.67)
1 0.99 (0.74, 
1.34)
0.92 (0.68, 
1.24)
0.77 (0.56, 
1.06)
OR (95% CI)b 1 0.84 (0.53, 
1.32)
0.93 (0.57, 
1.51)
1.01 (0.57, 
1.76)
1 0.91 (0.63, 
1.31)
0.85 (0.58, 
1.25)
0.64 (0.40, 
1.01)
Phenolic 
acids, mean 
(SD)
284.2 (87.3) 614.4 (61.8) 841.2 (173.7) 1488.1 
(301.4)
290.2 (86.3) 617.5 (60.7) 836.3 (171.5) 1450.9 (242.0)
OR (95% CI)a 1 0.94 (0.65, 
1.34)
1.11 (0.78, 
1.59)
0.88 (0.62, 
1.25)
1 0.82 (0.60, 
1.12)
0.80 (0.59, 
1.10)
0.67 (0.49, 
0.90)
OR (95% CI)b 1 0.96 (0.62, 
1.49)
0.98 (0.64, 
1.51)
0.92 (0.58, 
1.44)
1 0.70 (0.49, 
1.01)
0.75 (0.52, 
1.08)
0.64 (0.44, 
0.92)
Stilbenes, 
mean (SD)
0.005 (0.003) 0.017 (0.005) 0.046 (0.012) 0.525 (1.089) 0.004 (0.003) 0.017 (0.005) 0.046 (0.013) 0.575 (1.241)
OR (95% CI)a 1 0.99 (0.68, 
1.45)
0.88 (0.61, 
1.28)
0.88 (0.61, 
1.25)
1 0.86 (0.64, 
1.17)
0.81 (0.59, 
1.09)
0.78 (0.58, 
1.05)
OR (95% CI)b 1 0.98 (0.62, 
1.56)
0.74 (0.46, 
1.16)
0.71 (0.45, 
1.12)
1 0.85 (0.59, 
1.21)
0.77 (0.54, 
1.09)
0.84 (0.59, 
1.20)
Lignans, mean 
(SD)
0.16 (0.04) 0.24 (0.01) 0.31 (0.02) 2.09 (25.29) 0.16 (0.04) 0.24 (0.01) 0.31 (0.02) 1.86 (23.11)
OR (95% CI)a 1 0.84 (0.59, 
1.20)
1.03 (0.72, 
1.47)
1.03 (0.71, 
1.47)
1 1.31 (0.98, 
1.75)
0.94 (0.71, 
1.25)
1.06 (0.78, 
1.44)
OR (95% CI)b 1 1.06 (0.68, 
1.65)
1.09 (0.68, 
1.76)
1.29 (0.78, 
2.16)
1 1.24 (0.88, 
1.75)
1.05 (0.72, 
1.52)
1.40 (0.92, 
2.14)
Others, mean 
(SD)
6.1 (3.0) 17.0 (3.1) 32.9 (5.4) 77.3 (42.3) 6.56 (3.0) 16.7 (3.0) 32.6 (5.7) 76.8 (34.6)
OR (95% CI)a 1 1.01 (0.71, 
1.43)
1.15 (0.81, 
1.64)
084 (0.59, 
1.18)
1 0.99 (0.73, 
1.35)
0.75 (0.55, 
1.01)
0.60 (0.44, 
0.82)
OR (95% CI)b 1 1.18 (0.75, 
1.87)
1.29 (0.81, 
2.07)
0.87 (0.55, 
1.36)
1 1.21 (0.83, 
1.77)
0.87 (0.60, 
1.26)
0.61 (0.42, 
0.90)
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Table 3  Odds ratios (ORs) and 95% confidence intervals (CIs) for the association between individual polyphenol subclasses and incidence of 
hypertension
Polyphenol quartiles men Polyphenol quartiles women
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Phenolic acids
 Hydroxy-
benzoic 
acids, 
mean (SD) 
(mg/day)
43.5 (24.2) 85.8 (0.9) 91.7 (3.6) 156.9 (834.2) 44.6 (22.9) 85.7 (0.9) 91.8 (3.9) 159.4 (35.8)
 OR (95% 
CI)a
1 1.33 (0.87, 
2.04)
1.02 (0.67, 
1.55)
1.30 (0.85, 
1.98)
1 1.07 (0.77, 
1.48)
1.48 (1.05, 
2.07)
1.04 (0.76, 
1.45)
 Hydroxy-
cinnamic 
acids, 
mean (SD) 
(mg/day)
183.6 (73.9) 530.7 (65.6) 727.2 (177.3) 1391.2 
(297.2)
196.7 (76.1) 534.2 (62.9) 716.3 (160.0) 1351.8 (229.2)
 OR (95% 
CI)a
1 0.96 (0.62, 
1.48)
1.11 (0.73, 
1.69)
0.94 (0.62, 
1.42)
1 0.85 (0.59, 
1.21)
0.69 (0.48, 
0.98)
0.66 (0.47, 
0.93)
Flavonoids
 Flavanols, 
mean (SD) 
(mg/day)
324.1 (109.3) 520.2 (56.7) 681.8 (44.1) 1122.9 
(427.6)
327.1 (106.5) 526.4 (58.6) 681.5 (44.2) 1089.1 (348.1)
 OR (95% 
CI)b
1 0.74 (0.46, 
1.17)
0.86 (0.54, 
1.39)
0.81 (0.46, 
1.41)
1 1.08 (0.74, 
1.57)
0.68 (0.45, 
1.01)
0.55 (0.35, 
0.86)
 Flavonols, 
mean (SD) 
(mg/day)
59.9 (15.0) 89.8 (6.5) 113.6 (7.7) 161.7 (34.5) 60.5 (14.8) 89.3 (6.2) 113.1 (7.7) 166.9 (65.7)
 OR (95% 
CI)b
1 1.10 (0.69, 
1.76)
1.49 (0.90, 
2.45)
1.41 (0.79, 
2.54)
1 1.05 (0.72, 
1.54)
1.18 (0.78, 
1.78)
1.43 (0.90, 
2.27)
 Flavanones, 
mean (SD) 
(mg/day)
24.9 (11.3) 59.9 (11.2) 103.4 (15.7) 221.4 (90.2) 25.3 (11.2) 60.1 (11.1) 106.7 (15.7) 216.5 (87.0)
 OR (95% 
CI)b
1 0.91 (0.57, 
1.44)
0.84 (0.52, 
1.36)
0.88 (0.51, 
1.54)
1 1.35 (0.96, 
1.88)
1.52 (1.03, 
2.24)
1.46 (0.96, 
2.22)
 Flavones, 
mean (SD) 
(mg/day)
1.9 (0.7) 4.3 (0.7) 7.7 (1.5) 16.4 (6.4) 1.9 (0.6) 4.2 (0.7) 7.9 (1.5) 16.0 (6.4)
 OR (95% 
CI)b
1 1.02 (0.64, 
1.62)
0.88 (0.53, 
1.48)
0.92 (0.49, 
1.73)
1 0.84 (0.59, 
1.20)
0.84 (0.56, 
1.26)
0.71 (0.4, 1.15)
 Anthocya-
nins, mean 
(SD) (mg/
day)
4.4 (2.7) 8.7 (1.2) 14.4 (2.4) 86.2 (133.5) 4.4 (1.9) 8.8 (1.2) 14.4 (2.4) 106.2 (234.0)
 OR (95% 
CI)b
1 0.79 (0.48, 
1.29)
0.86 (0.52, 
1.41)
0.94 (0.55, 
1.60)
1 1.52 (1.04, 
2.21)
1.52 (1.03, 
2.25)
1.31 (0.88, 
1.94)
 Isoflavones, 
mean (SD) 
(mg/day)
0.0005 
(0.002)
0.140 (0.001) 0.196 
(0.0002)
4.219 (6.287) 0.001 (0.001) 0.140 (0.001) 0.196 (0.001) 5.534 (11.172)
 OR (95% 
CI)b
1 0.78 (0.46, 
1.30)
1.01 (0.58, 
1.77)
1.09 (0.63, 
1.88)
1 1.12 (0.77, 
1.64)
1.05 (0.68, 
1.60)
0.91 (0.60, 
1.38)
 Dihydroch-
alcones, 
mean (SD) 
(mg/day)
1.8 (1.2) 6.8 (1.7) 9.7 (0.9) 25.1 (7.9) 1.9 (1.2) 7.0 (1.6) 9.7 (1.0) 24.9 (7.6)
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the same cohort and testing the baseline relation between 
dietary polyphenol and presence of metabolic syndrome 
[21]; the study showed that among the main polyphenol 
classes, phenolic acids, flavonoids, and stilbenes were asso-
ciated with lower odds of hypertension [21]. To date, only 
a limited number of epidemiological studies evaluated the 
association between total and individual classes of dietary 
polyphenols and cardiovascular outcomes, including hyper-
tension [13, 14]. Despite no significant results were found 
in the analysis including total dietary polyphenol intake 
in a study conducted on Iranian adults, among individual 
classes sub-analyses revealed that phenolic acids and fla-
vonoids were negatively associated with blood pressure, 
whereas flavonoids and stilbenes were negatively associated 
with hypertension [13]. Another study conducted in the 
context of the PREDIMED (PREvencion con DIeta MEDi-
terranea) cohort reported lower prevalence of hypertension 
among individuals with higher intake of dietary polyphe-
nols [14] and further investigation in subgroup analysis 
revealed that also total polyphenols excretion was associ-
ated with blood pressure levels and prevalence of hyperten-
sion [22] as well as with plasma nitric oxide production, 
which is a well-known regulating factor of endothelial 
function [23]. Human diet contains a great variety of poly-
phenols but only some compounds and derivatives are bio-
actively relevant to endothelial function [24]. Moreover, 
differences in polyphenol food content databases and food 
items ascertained on dietary questionnaires may justify 
lack of significant findings in some of the aforementioned 
observational studies. In this study, we showed a wide pic-
ture of the possible association between polyphenol intake 
and hypertension, suggesting that independent associations 
of several polyphenol classes may exist, despite a concomi-
tant and an overall synergic effect in preventing could be 
determinant in preventing hypertension. Up to date, this is 
one of the most comprehensive studies in terms of polyphe-
nols investigated simultaneously considering hypertension 
as the outcome.
Results from this study may explain, at least in part, 
previous findings from meta-analyses of randomized con-
trolled trials regarding the effect of flavonoids in lowering 
blood pressure, as they have been reported to be effective 
in hypertensive patients, but not in normotensive individu-
als [25, 26]. We reported that flavonoids were significantly 
associated with incident cases of hypertension when con-
sidered separately in the individual class analysis. Regard-
ing subclasses of flavonoids, findings are contrasting and 
generally limited to some groups, such as anthocyanins [7] 
and isoflavone [8]. We did not found any significant result 
regarding these aforementioned subgroups of flavonoids, 
rather limited to flavanols. Literature on flavanol-rich food 
is wide, and findings from the few existing clinical trials 
show a potential blood pressure lowering effects of cocoa 
[27], while evidence on anthocyanins is contrasting [28, 
29]. There is also evidence on the HAPIEE cohort that 
high adherence to dietary patterns rich in fruit and vegeta-
ble (among the main sources of flavonoids) were associated 
with better health outcomes compared to lower adherence 
[30–32]. Flavonoids have been hypothesized to exert ben-
eficial effects in cardiovascular health by ameliorating the 
inflammatory status at various levels, for instance decreas-
ing circulating levels of TNF-α and IL-6 [33]. Regarding 
their potential effects on blood pressure, flavonoids can act 
as inhibitors of endothelial NAD(P)H oxidase [34, 35], an 
enzyme implicated in the regulation of NO metabolism in 
the vascular endothelium, which in turn regulate vasodila-
tory processes associated with blood flow. Indeed, inges-
tion of pure epicatechin in humans has been demonstrated 
to increase NO bioavailability and to acutely reduce plasma 
concentrations of endothelin-1, which is a potent endothe-
lium-derived vasoconstrictor [36]. Among other potential 
mechanisms of actions, flavonoids lower the activity of 
arginase-2, which is an enzyme that competes with NO 
synthase for l-arginine [37] and inhibit activity on angio-
tensin-converting enzyme in vitro [38].
Among the most studied hydroxycinnamic acids, chloro-
genic acids (CGAs) (compounds richly contained in coffee) 
contained in coffee have been reported to exert beneficial 
effects towards CVD risk factors and metabolic disorders 
[39]. Meta-analyses of experimental studies CGAs reported 
significant reduced blood pressure compared placebo treat-
ment [40], whereas results of observational studies on 
a Multivariate analyses were adjusted for age, total energy intake, body mass index, physical activity, educational status, smoking status, alcohol 
consumption, sodium, potassium and fiber intake, menopausal status (women only), and phenolic acid subclasses listed in the table
b Multivariate analyses were adjusted for age, total energy intake, body mass index, physical activity, educational status, smoking status, alcohol 
consumption, sodium, potassium and fiber intake, menopausal status (women only), and flavonoids subclasses listed in the table
Table 3  (continued)
Polyphenol quartiles men Polyphenol quartiles women
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
 OR (95% 
CI)b
1 0.94 (0.61, 
1.46)
1.39 (0.85, 
2.27)
1.19 (0.72, 
1.96)
1 0.97 (0.68, 
1.38)
1.01 (0.69, 
1.47)
1.40 (0.93, 
2.09)
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coffee consumption and hypertension showed a U-shaped 
association [41] and overall lower risk of metabolic syn-
drome [42]. Previous studies conducted on the HAPIEE 
cohort showed an inverse association between coffee con-
sumption and metabolic syndrome and risk of hypertension 
[43, 44]. Together to their anti-oxidant properties, CGAs 
have been found to exert direct effects in regulation of 
blood pressure, as well as glucose and lipids metabolism 
[45]. CGAs have been hypothesized (i) to exert antihyper-
tensive effects attenuating oxidative stress (reactive oxygen 
species) by reducing NAD(P)H-dependent super-oxide pro-
duction and ameliorating endothelial dysfunction and (ii) 
to interact with the renin–angiotensin aldosterone system 
by inhibiting angiotensin-converting enzyme activity both 
in vitro and in vivo [46, 47].
Studies on stilbenes have been mostly focused on the 
effects of resveratrol on cardio-metabolic health [48, 
49], revealing that resveratrol consumption significantly 
decreases systolic blood pressure at high dose [50]. We 
found inconclusive results on the risk analysis regarding the 
association between dietary stilbenes intake and hyperten-
sion risk, despite a linear association with individual intake 
and blood pressure measurements was found in men. Previ-
ous inconclusive prospective investigations on resveratrol 
efficacy on CVD outcomes suggested that the main limi-
tation of studying stilbenes intake relied on the very small 
amount consumed [51]. The present study may be affected 
by similar limitation, as contribution of “normal” diets in 
stilbenes is generally negligible and, thus difficult to accu-
rately estimate and associate with health outcomes [52].
Besides the most studied polyphenol classes, in this 
study, we opened the debate on other classes of polyphe-
nols that may exert beneficial effects toward uncontrolled 
blood pressure and have not been previously explored in 
epidemiological studies. This study adds evidence that 
other polyphenols, such as tyrosol, may play an important 
role in decreasing the risk of hypertension. Studies on less 
studied polyphenols are highly warranted because they 
could explain the favorable effects of foods high in such 
compounds that have been inversely associated with hyper-
tension risk. For instance, tyrosol and hydroxytyrosol con-
tained in olive oil [53, 54] and some alcoholic beverages 
[55, 56] have been reported to reduce blood pressure, and 
may explain the beneficial effects related to cardiovascu-
lar prevention by consumption of the aforementioned food 
sources (moderate for alcohol). More research is needed 
on this topic, and further evidence will help to overcome 
potential limitation of observational studies on dietary 
polyphenol intake and health outcomes.
Strengths of the present study are prospective design, 
large size, and reliable assessment of individual diet. How-
ever, some methodological issues should be addressed 
when considering results from this study. First, we cannot 
conclude causation due to observational study design. Sec-
ond, baseline evaluation of food intake may have intro-
duced misclassification, because diet may have changed 
over the follow-up period. Third, certain polyphenol-rich 
foods, such as herbs and spices, may not have been entirely 
captured by the FFQ. Forth, use of table content databases 
would have inevitably led to some misclassification of 
polyphenol intake. However, such issues are common to 
all previous studies using the same methodology, and since 
polyphenol exposure was ascertained before diagnosis 
of disease, misclassification would tend to bias estimates 
toward the null and underestimate true associations. Finally, 
we found significant results only among women. A possible 
explanation is the natural differences occurring in men and 
women due to hormonal protection in the latter. However, 
potential differences need to be further investigated.
In conclusions, we reported that higher intake of some 
classes of polyphenols are associated with lower risk of 
hypertension. Results from the present study underline the 
importance of investigating all classes of polyphenols as 
possible determinants of health outcomes. Further studies 
are needed to clarify whether polyphenol classes consumed 
in small amounts may exert beneficial effects on health if 
consumed in higher concentrations and to establish the 
effects specifically attributed to each polyphenol class.
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